Sanofi Business Development at a Glance

Last Modified Date: February 16, 2018

Consistently ranked one of the top 10 international pharmaceutical companies, Sanofi began 2018 with an acquisition spree to the tune of over USD 15 billion. Sanofi also has a large number of assets currently in Phase III, so expect to see a spike in announcements from those trials soon.

Sanofi Stock

Sanofi SA
Company Type: Large Pharma
Region: France, Worldwide
Cash Position: EUR 10 315M
Therapeutic Focus: Diabetes and Cardiovascular Diseases, Oncology, Immunology, Multiple Sclerosis, Rare Diseases, Vaccines


Deal Activity

Sanofi Data

Figure 1. Sanofis AG. In-Licensing Deals and Acquisitions, 2013 through present (February 2018)

Recent Deal Highlights:

ACQUISITION OF ABLYNX NANOBODY TECHNOLOGY PLATFORM

Total Size: EUR 3 900M | Therapeutic Area: Immunology, Immuno-Oncology/Inflammation, Oncology, Hematology, Respiratory | Date: January 2018

PRESS

ACQUISITION OF BIOVERATIVE HEMATOLOGY PROGRAMS

Total Size: USD 11 600M | Therapeutic Area: Hematology, Genetics | Date: January 2018

PRESS

RESTRUCTURE OF GENZYME-ALNYLAM PHARMACEUTICALS 2014 RNAI DEAL FOR HEMATOLOGY THERAPEUTICS

Therapeutic Area: Hematology, Genetics | Date: January 2018

PRESS_2018 | SEC_2018 | PRESS_2014 | SEC_2014 | PRESS_2012

R&D PIPELINE

Sanofi Pipeline

Figure 2. Sanofi SA. R&D Pipeline at present (February 2018)

Products from Recent Deals:

ACQUIRED PROTEIN SCIENCES QUADRIVALENT INFLUENZA VACCINES PROGRAM

Disease Area: Vaccines | Status: Multi-Dose Quadrivalent Influenza Vaccine Phase III

LEXICON PHARMACEUTICALS PARTNERED SOTAGLIFLOZIN SGLT-1 AND SGLT-2 DUAL INHIBITOR

Disease Area: Diabetes and Cardiovascular Diseases | Status: Diabetes 2 / Renal Impairment Phase III | Sotagliflozin with Metformin and Sulfonylurea Phase III | Heart Failure Phase II | Sotagliflozin with Hydrochlorothiazide Phase I | Sotagliflozin with Ramipril Phase I

HANMI PHARMACEUTICALS PARTNERED EFPEGLENATIDE GLUCAGON-LIKE-PEPTIDE-1 RECEPTOR AGONIST

Disease Area: Diabetes and Cardiovascular Diseases | Status: Diabetes 2 Phase III

BUSINESS DEVELOPMENT TEAM

Where did the data come from? The data and visualizations in this post come from the MotionHall OutMatch predictive out-licensing software.

How can I see more? Join the MotionHall platform today to access business development insights gleaned from data and predictive analytics.